# A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

> **NCT04442126** · PHASE1,PHASE2 · TERMINATED · sponsor: **Numab Therapeutics AG** · enrollment: 52 (actual)

## Conditions studied

- Advanced Solid Tumor
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Squamous Cell Carcinoma
- Ovarian Carcinoma
- Peritoneal Carcinoma
- Fallopian Tube Cancer
- Head and Neck Squamous Cell Carcinoma
- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** NM21-1480

## Key facts

- **NCT ID:** NCT04442126
- **Lead sponsor:** Numab Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-19
- **Primary completion:** 2024-02-06
- **Final completion:** 2024-02-06
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442126, "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04442126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*